Magnetic resonance imaging (MRI) is an invaluable tool for the diagnosis and monitoring of patients with multiple sclerosis (MS) as well as for the study of the disease pathophysiology. Because of its strong clinical, radiological and histopathological similarities with the human disease, experimental autoimmune encephalomyelitis (EAE) in the common marmoset has been studied more intensively over the past several years. Here, we review the current knowledge on MRI in the marmoset EAE, and we outline the physiopathological significance and translational values of these studies with respect to MS. Accumulating evidences suggest that the application of conventional, as well as non-conventional, MRI techniques in the marmoset EAE is a promising approach to elucidate the pathological processes underlying the development of inflammatory demyelinated lesions in the central nervous system, potentially improving the identification and development of new therapeutics.
Introduction
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) pathologically characterized by the presence of focal demyelinated lesions in brain and spinal cord (Lassmann et al., 2007; Hohlfeld et al., 1995) . Clinically, the most common form of MS begins with a relapsing remitting (RR) phase, characterized by neurological symptoms that partially or fully recover within days or weeks. Patients can remain in this phase for the whole life (~20% cases, benign MS (Hawkins and McDonnell, 1999) ) or switch to a progressive phase, named secondary progressive (SP) MS, characterized by accumulation of clinical disability over time. Although overt inflammation plays a major role in the first RR phase of the disease, the progressive phase seems mainly characterized by neurodegeneration with mostly compartmentalized inflammation (Absinta et al., 2015; Fischer et al., 2013) .
At present, valid therapeutic options are available only for the RR phase of MS and no curative treatment exists. Indeed, the available treatments are more effective early in the course of the disease, when tissue damage and neurodegenerative processes are still minimal or absent. In order to further improve knowledge on the early treatable phase of the disease, recent research has been focusing on the sequence of events underlying the development of inflammatory lesions (Frohman et al., 2006) . Although the "primum movens" determining these lesions to develop in the CNS is still largely unknown, an autoimmune reaction directed against CNS components, developing in a genetically and environmentally suitable background, is thought to be the base of this disease (t Hart and Massacesi, 2009). In this context, the close immunopathological similarities between the lesions observed in MS and in experimentally induced autoimmune encephalomyelitis (EAE) allowed to consider EAE a valid model of the effector pathogenic mechanisms of MS (t Hart and Massacesi, 2009).
Advantages and limits of the EAE model
The EAE model indeed is a well characterized model of CNS autoimmunity. The disease is induced by immunization of recipient animals with CNS antigens or myelin components together with an adjuvant, causing an autoimmune reaction against the CNS. EAE can be induced in a large variety of species (Baxter, 2007) , but only a few forms of EAE are both clinically and pathologically close to MS. Indeed, the clinical and pathological features of this disease vary among the different species in which it was induced (mice, rats, rabbits, guinea pigs and monkeys) and among different models (based on the type of myelin antigen used to induce the disease), ranging from an acute monophasic disease to a relapsing-remitting one closer to human MS (t Hart and Massacesi, 2009).
Both in MS and EAE, the histopathology of the acute lesions, is characterized by inflammatory infiltrates, mostly lymphocytes and macrophages, cuffed around post capillary venules (Baxter, 2007) . Despite a substantial histopathological similarity, the main difference between the two diseases is the artificial induction of autoimmunity in EAE whereas the causes of MS are less clear. Thus the first phase (afferent
